Profound Medical financials
$5.72−3.38%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q4 '22 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5M | $5.3M | $6.0M | $5.3M | $2.2M | $2.6M | $4.2M | $2.8M | $2.2M | $1.4M | — | — |
| Gross profit | $1.9M | $3.8M | $4.0M | $3.9M | $1.6M | $1.9M | $3.0M | $1.8M | $1.4M | $866.0K | — | — |
| Gross margin | 78.4% | 71.8% | 66.8% | 74.3% | 73.2% | 70.7% | 70.9% | 63.1% | 63.6% | 60.2% | — | — |
| Operating income | -$11.1M | -$8.0M | -$7.4M | -$8.9M | -$13.8M | -$11.2M | -$8.3M | -$9.0M | -$7.8M | -$7.9M | — | — |
| Net income | -$9.5M | -$7.1M | -$8.2M | -$8.0M | -$15.7M | -$10.7M | -$4.9M | -$9.4M | -$6.9M | -$6.6M | — | — |
| Net margin | −384.2% | −132.2% | −136.8% | −150.8% | −709.9% | −409.2% | −118.5% | −330.7% | −309.9% | −457.6% | — | — |
| Diluted EPS | $-0.26 | $-0.19 | $-0.27 | $-0.26 | $-0.52 | $-0.36 | $-0.19 | $-0.38 | $-0.28 | $-0.27 | — | — |
| EBITDA | -$10.9M | -$7.9M | -$7.3M | -$8.8M | -$13.7M | -$11.0M | -$8.1M | -$8.8M | -$7.6M | -$7.6M | $0.00 | $0.00 |
| Operating cash flow | -$11.3M | -$8.6M | -$6.6M | -$9.6M | -$13.7M | -$8.3M | -$5.9M | -$6.8M | -$6.2M | -$4.5M | — | — |
| Free cash flow | -$11.3M | -$8.6M | -$6.7M | -$9.6M | -$13.7M | -$8.3M | -$5.9M | -$6.8M | -$6.2M | -$4.5M | — | — |
| Diluted shares | 36.4M | 36.3M | 30.7M | 30.1M | 30.1M | 30.0M | 25.8M | 24.5M | 24.4M | 24.3M | 21.2M | 20.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $38.3M | $50.3M | $59.7M | $24.8M | $35.2M | $46.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $4.5M | $4.5M | $4.5M | $4.5M | $4.5M | $4.5M |
| Total assets | $62.4M | $73.5M | $77.5M | $42.3M | $49.7M | $60.9M |
| Total liabilities | $12.6M | $14.0M | $11.0M | $10.2M | $10.4M | $10.1M |
| Shareholders' equity | $49.8M | $59.4M | $66.4M | $32.1M | $39.3M | $50.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology